Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Stock Analysis

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Healthcare & Pipeline Overview

Bristol-Myers Squibb PFD CONV 2 (BMYMP) is a pharmaceutical company focused on discovering, developing, and marketing drugs, particularly in immuno-oncology. With a 14.6% profit margin and a 4.17% dividend yield, the company generates approximately 70% of its revenue from the U.S. market, operating within the broader healthcare sector.

What Is the Investment Thesis for BMYMP?

Bristol-Myers Squibb PFD CONV 2 presents a mixed investment thesis. The company's strong presence in immuno-oncology and a solid 14.6% profit margin offer potential upside. A dividend yield of 4.17% provides income for investors. However, the company's high dependence on the U.S. market (70% of sales) exposes it to regulatory and market risks specific to that region. The company's beta of 0.27 suggests lower volatility compared to the broader market. Upcoming catalysts in their drug pipeline and potential expansion into new markets could drive future growth. Investors should carefully weigh these factors, considering the competitive landscape and potential regulatory changes.

Based on FMP financials and quantitative analysis

BMYMP Key Highlights

Market capitalization of $815B indicates a large and established company within the pharmaceutical industry.

• P/E ratio of 16.2 suggests the company is reasonably valued compared to its earnings.
• Profit margin of 14.6% demonstrates strong profitability in the competitive pharmaceutical market.
• Gross margin of 67.6% reflects efficient cost management in drug manufacturing and sales.
• Dividend yield of 4.17% provides a substantial return to investors, making it attractive for income-seeking portfolios.

Who Are BMYMP's Competitors?

BMYMP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BMYMP's Key Strengths?

Strong presence in immuno-oncology.

• High gross margin of 67.6%.
• Significant market capitalization.
• Established brand reputation.

What Are BMYMP's Weaknesses?

High dependence on the U.S. market.

• Exposure to drug pricing pressures.
• Reliance on patent protection.
• Potential for biosimilar competition.

What Could Drive BMYMP Stock Higher?

Potential FDA approval of new drug candidates in the pipeline.

• Expansion into new geographic markets, particularly in emerging economies.
• Strategic partnerships and collaborations with other pharmaceutical companies.
• Results from ongoing clinical trials for key drug candidates.
• Increasing demand for immuno-oncology therapies.

What Are the Key Risks for BMYMP?

Regulatory changes in the U.S. healthcare system could impact drug pricing and reimbursement.

• Increasing competition from other pharmaceutical companies in key therapeutic areas.
• Patent expirations could lead to generic competition and reduced revenue.
• Economic downturns could affect healthcare spending and demand for pharmaceutical products.
• Product liability lawsuits and other legal challenges.

What Are the Growth Opportunities for BMYMP?

• Expansion into Emerging Markets: Bristol-Myers Squibb has the opportunity to expand its presence in emerging markets, such as Asia-Pacific and Latin America. These regions are experiencing rapid economic growth and increasing healthcare spending, creating a significant demand for pharmaceutical products. By establishing strategic partnerships and tailoring its product offerings to local needs, Bristol-Myers Squibb can tap into these high-growth markets and diversify its revenue streams.
• Development of Novel Therapies in Oncology: Bristol-Myers Squibb can capitalize on its expertise in immuno-oncology by developing novel therapies for various types of cancer. By investing in research and development and pursuing strategic collaborations, Bristol-Myers Squibb can bring innovative cancer treatments to market and capture a significant share of this growing market. The timeline for this growth opportunity is dependent on clinical trial outcomes and regulatory approvals, typically spanning several years.
• Strategic Acquisitions and Partnerships: Bristol-Myers Squibb can pursue strategic acquisitions and partnerships to expand its product portfolio and gain access to new technologies. The pharmaceutical industry is characterized by frequent mergers and acquisitions, as companies seek to strengthen their competitive position and diversify their offerings. By acquiring companies with promising drug candidates or innovative technologies, Bristol-Myers Squibb can accelerate its growth and enhance its long-term prospects. The timing and impact of these acquisitions are difficult to predict, but they can significantly alter the company's growth trajectory.
• Focus on Personalized Medicine: Bristol-Myers Squibb can leverage advancements in genomics and diagnostics to develop personalized medicine solutions tailored to individual patients. Personalized medicine involves using a patient's genetic information to select the most effective treatment options, improving outcomes and reducing side effects. By investing in personalized medicine research and developing companion diagnostics, Bristol-Myers Squibb can differentiate its products and capture a growing share of the market for targeted therapies. The personalized medicine market is expected to grow substantially over the next decade, driven by technological advancements and increasing adoption by healthcare providers.
• Expansion of Digital Health Solutions: Bristol-Myers Squibb can expand its offerings in digital health solutions, such as mobile apps and wearable devices, to improve patient engagement and adherence to treatment regimens. Digital health solutions can provide patients with personalized support, track their progress, and facilitate communication with healthcare providers. By developing and integrating digital health solutions into its product offerings, Bristol-Myers Squibb can enhance patient outcomes and strengthen its relationships with healthcare providers. The digital health market is experiencing rapid growth, driven by increasing adoption of mobile technology and growing demand for remote patient monitoring.

What Are BMYMP's Competitive Advantages?

• Patent protection for its innovative drugs provides a period of market exclusivity.
• Strong brand reputation and established relationships with healthcare providers.
• Extensive research and development capabilities enable the company to develop new products.
• Regulatory expertise in navigating the complex drug approval process.

What Does BMYMP Do?

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases. The company's history is rooted in the late 19th century, evolving through mergers and acquisitions to become a leader in the pharmaceutical industry. Bristol-Myers Squibb's primary focus is on therapeutic areas such as oncology, hematology, immunology, cardiovascular, and neuroscience. Its key products include innovative treatments for various cancers, immune disorders, and cardiovascular conditions. The company operates globally, with a significant presence in the United States, which accounts for approximately 70% of its total sales. Bristol-Myers Squibb competes with other major pharmaceutical companies, focusing on research and development to maintain its competitive edge and expand its portfolio of innovative medicines. The company employs approximately 34,100 individuals and is headquartered in Princeton, New Jersey.

What Products and Services Does BMYMP Offer?

• Discovers and develops pharmaceutical products.
• Markets and sells prescription medications.
• Focuses on therapeutic areas like oncology, immunology, and cardiovascular diseases.
• Conducts clinical trials to evaluate the safety and efficacy of new drugs.
• Manufactures pharmaceutical products.
• Engages in research and development to identify new drug targets and therapies.
• Works with regulatory agencies to obtain approval for new drugs.

How Does BMYMP Make Money?

• Develops and patents innovative pharmaceutical products.
• Generates revenue through the sale of prescription medications.
• Invests heavily in research and development to create new products.
• Markets products to healthcare providers and patients.

What Industry Does BMYMP Operate In?

Bristol-Myers Squibb operates in the highly competitive drug manufacturing industry, characterized by intense research and development, stringent regulatory requirements, and patent protection. Bristol-Myers Squibb competes with major players like AZNCF, BAYRY, CHGCF, CHGCY, and GLAXF, all vying for market share in key therapeutic areas. The industry is also influenced by factors such as drug pricing pressures, biosimilar competition, and healthcare reforms.

Who Are BMYMP's Key Customers?

• Patients who require prescription medications for various diseases.
• Healthcare providers, including physicians, hospitals, and clinics.
• Pharmacies that dispense prescription medications.
• Government and private healthcare insurers.

Wall Street analysts project Bristol-Myers Squibb Company PFD CONV 2 revenue of about $46.91B for fiscal 2026, with EPS near $6.26.

Quarterly Financial Performance: Bristol-Myers Squibb Company PFD CONV 2

Revenue for Bristol-Myers Squibb Company PFD CONV 2 came in at $12.97B during Q2 2026, a 12.9% improvement versus the preceding quarter. The company recorded net income of $3.32B, with diluted EPS of $1.62. Quarter-over-quarter revenue has been mixed, typical for a mega-cap company operating in Healthcare. Across the four most recent quarters, BMYMP averaged $1.14 in diluted EPS.

BMYMP Valuation & Market Position

With a $815B market cap, Bristol-Myers Squibb Company PFD CONV 2 sits in the mega-cap segment of the market.

Return on equity for Bristol-Myers Squibb Company PFD CONV 2 stands at 26.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.4%, showing how much profit it generates from its asset base. BMYMP trades at a trailing price-to-earnings ratio of 16.18, below the Healthcare sector average of ~23x. Its free cash flow yield is 1.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 14.9%, the inverse of the P/E and a quick read on earnings relative to price.

Bristol-Myers Squibb Company PFD CONV 2's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 8.63 places it in the safe zone, indicating low near-term bankruptcy risk.

Company Profile

Bristol-Myers Squibb Company PFD CONV 2 operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Princeton, US. The company is led by CEO Christopher S. Boerner. BMYMP has traded publicly since 2003.

BMYMP Financials

BMYMP Latest News

Bristol-Myers Squibb Company PFD CONV 2 Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources